Phase 2 N=19 Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
Kaposi's Sarcoma · HIV Infections · HIV Seronegativity
Primary: Response Rate — 31 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=16 Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma
Sarcoma, Kaposi
Primary: Overall Response Rate (ORR) of Six Cycles of Liposomal Doxorubicin Combined With Bevacizumab in Patients With Advanced KS. — 50; 67 percentage of participants
Phase 2 N=28 Pomalidomide for Kaposi Sarcoma in People With or Without HIV
Kaposi Sarcoma · Sarcoma, Kaposi
Primary: Number of Participants With Grades 1-4 Adverse Events That Are Possibly, Probably, and/or Definitely Attributed to Pomalidomide — 21; 10; 1; 0 Participants
Phase 3 N=192 Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
HIV-1 Infection · Kaposi's Sarcoma
Primary: Kaposi Sarcoma (KS) Status at Week 48 Compared to Study Entry — 43; 47; 13; 9 Participants — p=0.911
Phase 2 N=23 sEphB4-HSA in Treating Patients With Kaposi Sarcoma
Skin Kaposi Sarcoma
Primary: Proportion of Participants Experiencing Clinical Response — 56.5 percentage of participants
N/A N=6 Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
Sarcoma
Primary: Tumor Response Rate Every 4 Weeks — 4; 1 participants
Phase 2 N=13 Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)
Kaposi's Sarcoma
Primary: Number of Participants With a Decrease in Kaposi's Sarcoma (KS) Total Surface Area — 11 Participants
N/A N=29 Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions
Kaposi's Sarcoma
Primary: Preliminary Assessment of the Temperature of Kaposi's Sarcoma Lesions Compared to the Temperature in the Normal Skin Measured With Thermography — 1.1 Celsius
Phase 2 N=14 Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Kaposi´s Sarcoma
Primary: Number of Participants With Complete Response — 1; 3 participants
Phase 2 N=26 Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection
Human Immunodeficiency Virus 1 Positive · Skin Kaposi Sarcoma
Primary: Overall Response Rate — 0.577 proportion of participants
Phase 2 N=3 Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
AIDS-Related Kaposi Sarcoma · Recurrent Kaposi Sarcoma
Primary: Maximum Tolerated Dose of Lenalidomide Defined as the Dose Level at Which 0/6 or 1/6 Subjects Experience Dose Limiting Toxicity (DLT) With the Next Higher Dose Having at…
Phase 2 N=40 Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.
Kaposi Sarcoma · Human Immunodeficiency Virus · Immune Reconstitution Syndrome
Primary: Number of Participants Who Died of Immune Reconstitution Inflammatory Syndrome Associated to Kaposi Sarcoma (IRIS-KS) — 0; 3 Participants
Phase 2 N=30 Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
Sarcoma
Primary: Proportion of Patients Who Achieve a Clinical Response — 0.33 proportion
Phase 2 N=36 Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
Recurrent Kaposi Sarcoma · Skin Kaposi Sarcoma
Primary: Efficacy of Therapeutic Escalation of Standard Dose Nelfinavir, Followed by High Dose Nelfinavir, for Treatment of Kaposi Sarcoma Lesions for HIV Positive Participants…
Phase 1 N=15 An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
Kaposi Sarcoma · HIV Infections
Primary: To Determine the Safety of Escalating Doses of Tc 99m Tilmanocept in HIV Subjects With Biopsy-confirmed KS. — 0; 0; 0 Safety Signals
Phase 2 N=15 A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
Kaposi's Sarcoma · HIV Positive · AIDS
Primary: Objective Response Rate — 0; 7; 6 Participants
Phase 2 N=8 Tocilizumab for KSHV-Associated Multicentric Castleman Disease
Castleman Disease · Multicentric Castleman Disease · Giant Lymph Node Hyperplasia
Primary: Percentage of Participants With an Overall Clinical Benefit Response — 63; 100; 50; 67 percentage of participants
N/A N=10 Evaluating Quality of Life in Patients With AIDS-Associated Kaposi Sarcoma Treated With Bleomycin and Vincristine
AIDS-Related Kaposi Sarcoma · Human Immunodeficiency Virus 1 Positive
Primary: Total Score on Quality of Life Assessed Using Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire — 56.9 score on a scale
Phase 2 N=5 Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT
Kaposi's Sarcoma
Primary: Localization — 5 participants
Phase 3 N=334 Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS
HIV-1 Infection
Primary: Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART — 19.7; 49.8 Cumulative events per 100 persons
Phase 3 N=275 Open-label Study of ASP2151 in Herpes Simplex Patients
Herpes Simplex
Primary: Percentage of Participants With Healing by Day 8 — 194 Participants
Phase 4 N=19 Use of Cidofovir for Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis
Primary: Change in Papilloma Severity — 13.2; 12; 3.7; 3.6 scores on a scale
Phase 2 N=1 Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Peripheral T-cell Lymphoma · Cutaneous T-cell Lymphoma
Primary: Global Composite Response (Skin, Blood, Lymph Nodes)as Determined by Skin Evaluations, Blood Counts and PET/CT Imaging — 260; 260; 232 days
Phase 2 N=40 ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
Skin Cancer
Primary: Number of Participants With Objective Response (Partial Response, Stable Disease and Progressive Disease) — 14; 4; 19 participants
N/A N=8 Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva
Vulvar Cancer
Primary: Percentage of Participants With Clinical and Histologic Remission — 75 % of participants
Phase 1 N=36 Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1)
HSV · Herpes Labialis
Primary: Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline — 10.073; 11.380; 10.711; 11.431 q-RT-PCR crossing threshold cycle (Ct)
Phase 3 N=52 Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
Genital Warts
Primary: Change in the Maximum Size of the Genital Wart Lesion Over the Trial Period (as Measured in mm) — 8; 6; 11; 7 Participants
Phase 2 N=15 Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
Phase 2 N=8 Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
Squamous Cell Carcinoma of Skin · Carcinoma, Squamous Cell
Primary: Objective Response Rate (ORR) — 4; 1; 1 Participants
Phase 4 N=45 Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
Prophylaxis Of Invasive Fungal Infections
Primary: Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit — 3 participants